AbbVie (NYSE:ABBV) Shares Down 1% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV)’s share price dropped 1% during trading on Thursday . The company traded as low as $241.20 and last traded at $243.6380. 4,257,962 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 7,008,278 shares. The stock had previously closed at $246.20.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported robust second-quarter results, with adjusted earnings and revenue exceeding consensus estimates. Revenue increased 10.2% year over year, supported by continued growth from key medicines, and management raised its revenue outlook. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Allergan Aesthetics’ supplemental application for BOTOX Cosmetic in jawline treatment has been accepted for FDA review. Approval could expand BOTOX Cosmetic’s U.S. addressable market and further diversify AbbVie’s aesthetics portfolio. AbbVie Wins FDA Review for BOTOX Cosmetic
• Positive Sentiment: Analyst sentiment remains supportive: Erste Group upgraded AbbVie to “buy,” while Cantor Fitzgerald raised its price target to $285. The company’s dividend growth record also continues to attract income-focused investors. Cantor Fitzgerald Boosts AbbVie Price Target
• Neutral Sentiment: Several analysts remain bullish, but valuation has become a concern after AbbVie’s rally. A high earnings multiple leaves less room for execution disappointments, particularly as the Apogee transaction moves toward integration. Prediction: AbbVie Will End the Year at This Price
• Negative Sentiment: AbbVie reduced its 2026 EPS outlook to account for the Apogee acquisition, offsetting the positive impact of strong quarterly performance and higher revenue guidance. This earnings-impact concern appears to be the primary reason shares are under pressure. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the Apogee acquisition. The additional debt increases financing costs and leverage, creating near-term pressure on earnings and raising execution risk. AbbVie Prices $9.9 Billion of Senior Notes

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABBV. Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. HSBC reiterated a “buy” rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Guggenheim increased their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $298.00 price target on shares of AbbVie in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $272.76.

AbbVie Stock Down 1.0%

The firm has a market cap of $430.46 billion, a PE ratio of 68.82, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30. The business has a 50 day simple moving average of $240.90 and a two-hundred day simple moving average of $224.61.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ACT Advisors LLC. grew its holdings in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC grew its stake in shares of AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after purchasing an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC increased its holdings in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock valued at $359,000 after purchasing an additional 43 shares in the last quarter. Bank of Jackson Hole Trust lifted its stake in shares of AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the period. Finally, Leslie Global Wealth LLC lifted its stake in shares of AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock valued at $751,000 after purchasing an additional 44 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.